JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reardon, D. A.
Right arrow Articles by Zalutsky, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reardon, D. A.
Right arrow Articles by Zalutsky, M. R.

Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results

David A. Reardon1,2, Jennifer A. Quinn3, Gamal Akabani4, R. Edward Coleman4, Allan H. Friedman1, Henry S. Friedman1,2, James E. Herndon, II5, Roger E. McLendon6, Charles N. Pegram6, James M. Provenzale4, Jeannette M. Dowell5, Jeremy N. Rich3, James J. Vredenburgh3, Annick Desjardins3, John H. Sampson1, Sridharan Gururangan2, Terence Z. Wong4, Michael A. Badruddoja3, Xiao-Guang Zhao6, Darell D. Bigner6 and Michael R. Zalutsky4

1 Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina; 2 Department of Pediatrics, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina; 3 Department of Medicine, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina; 4 Department of Radiology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina; 5 Cancer Center Biostatistics, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina; and 6 Department of Pathology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina


Figure 1
View larger version (10K):

[in a new window]
  		FIGURE 1.  Treatment schema for each stratum.

 

Figure 2
View larger version (17K):

[in a new window]
  		FIGURE 2.  Kaplan–Meier overall survival estimates for newly diagnosed patients (A) and recurrent patients (B) after stratification by histology. AO = anaplastic oligodendroglioma.

 

Figure 3
View larger version (55K):

[in a new window]
  		FIGURE 3.  Serial MRI (top and middle) and 18F-FDG PET scan results of representative patient after 131I ch81C6 therapy. Corresponding 18F-FDG PET scan images (bottom) demonstrate a lack of increased metabolic activity in region of SCRC.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.